在存在病变时的多地图集:应用于多发性硬化症
Sandra González-Villà1,2, Yuankai Huo2, Arnau Oliver1
1Institute of Computer Vision and Robotics, University of Girona, Ed. P-IV, Campus Montilivi, 17003 Girona, Spain.
概括
这项研究引入了一种用于脑图像细分的新统计融合方法,通过将损伤和标签面具纳入非局部STAPLE框架,提高受伤大脑的准确性.
科学领域:
- 医疗图像分析 医学图像分析
- 计算神经科学是一种计算神经科学.
- 生物医学工程 生物医学工程
背景情况:
- 多地图集细分对于健康的大脑是有效的.
- 在受伤的大脑中,损伤的强度会破坏传统的细分.
- 现有的方法与病变干扰作斗争.
研究的目的:
- 为健康大脑和受伤大脑开发一个强大的多图表细分方法.
- 为了克服细分化中损伤强度的局限性,融合.
- 为了提高脑图像细分在存在病变的准确性.
主要方法:
- 使用非本地STAPLE框架重新制定统计融合方法.
- 整合一个损伤面具,以改善语音对应.
- 集成已知的标签面具用于强制标签决策和手动编辑集成.
主要成果:
- 拟议的方法表明,在损伤区域的细分精度有所提高.
- 定量和定性评估显示,与最先进的方法相比,性能优越.
- 这种方法有效地处理模拟和多发性硬化症 (MS) 患者的图像.
结论:
- 重构的统计融合方法对于对健康和受伤的大脑进行细分是有效的.
- 该方法成功地避免了损伤强度的干扰.
- 这种技术在多图书馆大脑细分方面取得了重大进展,特别是在病理病例中.
相关概念视频
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
Multiple Sclerosis l: Introduction
20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Huntington Disease l: Introduction
110
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
110


